CTI BioPharma Shares Drop 13% After Public Offering Prices
CTI BioPharma Shares Drop 13% After Public Offering Prices
DJ CTI BioPharma Shares Drop 13% After Public Offering Prices
By Chris Wack
CTI BioPharma Corp. shares were down 13% to $2.54 after the company priced its previously announced underwritten public offering of 14.3 million common shares and 600 shares of its series X1 preferred stock.
The company has granted the underwriters a 30-day option to purchase up to an additional 2.1 million shares.
The offering price to the public of a share of common stock is $2.50 and the offering price of series X1 stock is $25,000. Each share of series X1 stock will be convertible into 10,000 shares of common stock at the election of the holder.
All of the securities in the offering are being sold by CTI, which should see proceeds of $50.7 million from the offering.
The offering is expected to close on or about April 6.
CTI said it intends to use the proceeds from the proposed sale for commercialization activities for pacritinib, general working capital and corporate purposes.
Write to Chris Wack at chris.wack@wsj.com
(END) Dow Jones Newswires
April 01, 2021 10:54 ET (14:54 GMT)
Copyright (c) 2021 Dow Jones & Company, Inc.
DJ CTI BioPharma Shares Drop 13% After Public Offering Prices
DJ CTI BioPharma股價在公開募股價格後下跌13%
By Chris Wack
克里斯·瓦克(Chris Wack)著
CTI BioPharma Corp. shares were down 13% to $2.54 after the company priced its previously announced underwritten public offering of 14.3 million common shares and 600 shares of its series X1 preferred stock.
CTI BioPharma Corp.股價下跌13%，報2.54美元，此前該公司為之前宣佈的1,430萬股普通股和600股X1系列優先股的承銷公開發行定價。
The company has granted the underwriters a 30-day option to purchase up to an additional 2.1 million shares.
該公司已授予承銷商30天的選擇權，最多可額外購買210萬股票。
The offering price to the public of a share of common stock is $2.50 and the offering price of series X1 stock is $25,000. Each share of series X1 stock will be convertible into 10,000 shares of common stock at the election of the holder.
普通股的公開發行價為2.50美元，X1系列股票的發行價為2.5萬美元。根據持有者的選擇，X1系列股票的每股可轉換為10,000股普通股。
All of the securities in the offering are being sold by CTI, which should see proceeds of $50.7 million from the offering.
此次發行的所有證券都由CTI出售，CTI應該會從此次發行中獲得5070萬美元的收益。
The offering is expected to close on or about April 6.
預計此次發行將於4月6日左右結束。
CTI said it intends to use the proceeds from the proposed sale for commercialization activities for pacritinib, general working capital and corporate purposes.
CTI表示，它打算將擬議出售的收益用於帕利替尼的商業化活動、一般營運資金和企業用途。
Write to Chris Wack at chris.wack@wsj.com
寫信給克里斯·瓦克(chris.wack@wsj.com)
(END) Dow Jones Newswires
(完)道瓊通訊社
April 01, 2021 10:54 ET (14:54 GMT)
2021年4月1日美國東部時間10：54(格林尼治標準時間14：54)
Copyright (c) 2021 Dow Jones & Company, Inc.
版權所有(C)2021年道瓊斯公司
譯文內容由第三人軟體翻譯。
風險及免責聲明
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用瀏覽器的分享功能，分享給你的好友吧